

Rolf D Issels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4068742/publications.pdf>

Version: 2024-02-01

31
papers

2,313
citations

471509

17
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

2990
citing authors

#	ARTICLE	IF	CITATIONS
1	VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?. <i>Cancers</i> , 2022, 14, 1006.	3.7	2
2	A Heat-Activated Drug Delivery Platform Based on Phosphatidyl-(oligo)-Glycerol Nanocarrier for Effective Cancer Treatment. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000089.	3.6	12
3	Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer. <i>Cancers</i> , 2021, 13, 1279.	3.7	21
4	Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 147, 164-169.	2.8	13
5	Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 158, 123-132.	2.8	11
6	Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – a case report. <i>International Journal of Hyperthermia</i> , 2020, 37, 55-65.	2.5	8
7	Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma. <i>Cancers</i> , 2020, 12, 3612.	3.7	17
8	Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2020, 2020, 1-10.	1.3	6
9	A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1353-1362.	4.2	34
10	Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma – Reply. <i>JAMA Oncology</i> , 2019, 5, 114.	7.1	1
11	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2018, 4, 483.	7.1	227
12	Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e630.	10.7	5
13	Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair. <i>International Journal of Cancer</i> , 2016, 139, 467-479.	5.1	14
14	Regional hyperthermia for high-risk soft tissue sarcoma treatment: present status and next questions. <i>Current Opinion in Oncology</i> , 2016, 28, 447-452.	2.4	8
15	Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. <i>Oncolmmunology</i> , 2016, 5, e1178421.	4.6	15
16	Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application. <i>International Journal of Hyperthermia</i> , 2016, 32, 89-95.	2.5	84
17	Concomitant Trimodality Therapy of Re-irradiation, Chemotherapy and Regional Hyperthermia for a Pretreated Inoperable Sarcoma Recurrence. <i>Tumori</i> , 2015, 101, e54-e56.	1.1	2
18	VEGFR2 predicts decreased patients survival in soft tissue sarcomas. <i>Pathology Research and Practice</i> , 2015, 211, 726-730.	2.3	21

#	ARTICLE	IF	CITATIONS
19	Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection. <i>Annals of Surgery</i> , 2014, 260, 749-756.	4.2	61
20	Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier. <i>Journal of Clinical Pathology</i> , 2014, 67, 592-598.	2.0	40
21	Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. <i>Journal of Controlled Release</i> , 2012, 162, 400-406.	9.9	63
22	Hsp70, a messenger from hyperthermia for the immune system. <i>European Journal of Cell Biology</i> , 2012, 91, 48-52.	3.6	46
23	Hyperthermia in soft tissue sarcoma. <i>Current Treatment Options in Oncology</i> , 2011, 12, 12-20.	3.0	27
24	Hyperthermie. , 2011, , 265-272.		0
25	Size of thermosensitive liposomes influences content release. <i>Journal of Controlled Release</i> , 2010, 147, 436-443.	9.9	106
26	Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. <i>Lancet Oncology</i> , The, 2010, 11, 561-570.	10.7	576
27	Hyperthermia-Induced Targeting of Thermosensitive Gene Carriers to Tumors. <i>Human Gene Therapy</i> , 2008, 19, 1283-1292.	2.7	51
28	Hyperthermia adds to chemotherapy. <i>European Journal of Cancer</i> , 2008, 44, 2546-2554.	2.8	457
29	High-risk soft tissue sarcoma: Clinical trial and hyperthermia combined chemotherapy. <i>International Journal of Hyperthermia</i> , 2006, 22, 235-239.	2.5	18
30	Response to Neoadjuvant Chemotherapy Combined With Regional Hyperthermia Predicts Long-Term Survival for Adult Patients With Retroperitoneal and Visceral High-Risk Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2002, 20, 3156-3164.	1.6	110
31	Tumor-Derived Heat Shock Protein 70 Peptide Complexes Are Cross-Presented by Human Dendritic Cells. <i>Journal of Immunology</i> , 2002, 169, 5424-5432.	0.8	255